Now is the time to act to protect the world’s most vulnerable citizens with a GBS vaccine.”
762
全世界平均15%的孕妇（每年近2000万）在阴道内存在B组链球菌，通常没有症状。
An average of 15% of all pregnant women worldwide – nearly 20 million annually – carry the GBS bacterium in their vagina, usually without symptoms.
763
然而它会由孕妇传播到子宫中尚未出生的婴儿，或者在分娩过程中传给新生儿。
It can then spread from a pregnant woman to her unborn baby in the womb, or to newborns during labour.
764
目前，如果在妊娠期间发现该菌，在分娩过程中对产妇进行抗生素预防是预防新生儿B组链球菌病的主要手段。
Currently antibiotic prophylaxis administered to a woman during labour is the main means of preventing GBS disease in newborn infants, if the bacterium is detected during pregnancy.
However, even in regions with high prophylactic coverage, there remain significant health risks, since this intervention is unlikely to prevent most GBS associated stillbirths, preterm births, or GBS disease that occurs later after birth.
Importantly the largest burden of GBS is in low- and middle-income countries, where screening and intrapartum antibiotic administration are most challenging to implement, and a vaccine is therefore most urgently needed.
767
孕产妇B组链球菌感染死亡率最高的是撒哈拉以南非洲（约占全球负担的一半）以及东亚和东南亚。
The highest rates ofmaternal GBS are found in sub-Saharan Africa (accounting for around half of the global burden), and Eastern and South-Eastern Asia.
768
喀麦隆公共卫生部降低孕产妇、新生儿和儿童死亡率国家多部门规划协调员 Martina Lukong Baye 博士 也是报告撰稿人，她说：“针对B组链球菌的新型孕产妇疫苗将改变受影响最严重国家新生儿和孕产妇死亡率的下降趋势，特别是撒哈拉以南非洲，这些国家的死亡负担令人震惊。
Dr Martina Lukong Baye, Coordinator of the National Multisector Programme to Combat Maternal, Newborn & Child Mortality at the Ministry of Public Health in Cameroon, also a contributor to the report, said: “A new maternal vaccine against GBS would be a game-changer in the reduction of newborn and maternal deaths for the most affected countries - especially sub-Saharan Africa where the burden of these deaths is alarming.
769
我们呼吁所有利益攸关方将此作为道德优先事项。”
We plead to all stakeholders to treat this as a matter of moral priority.”
770
报告呼吁研究人员、疫苗开发者和资助者加速开发一种有效且可供孕妇在定期产检时接种的B组链球菌疫苗。
The report calls for researchers, vaccine developers and funders to accelerate development of an effective GBS vaccine that could be administered to pregnant women during routine pregnancy checkups.